Rockville’s MacroGenics Inc. is moving deeper into the cancer immunotherapy space with a new big pharma partnership.
The clinical-stage biopharmaceutical company, which focuses on antibody-based therapies for cancer treatment and other diseases, announced it will work with Merck to study one of its molecules to treat stomach cancer. The companies will evaluate the antibody created by MarcoGenics in combination with Merck’s immunotherapy drug Keytruda in a Phase 1b/2 clinical trial, officials said.
{iframe}http://www.bizjournals.com/washington/blog/2015/10/maryland-pharmaceutical-companyteams-with-merck-on.html?ana=e_du_pap&s=article_du&ed=2015-10-26&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1445887860{/iframe}